Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
JSPR Jasper Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: JSPR
Price (delayed)
$6.82
Market cap
$102.45M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.26
Enterprise value
$55.82M
Highlights
The EPS has declined by 8% since the previous quarter but it is up by 6% year-on-year
JSPR's quick ratio has dropped by 70% year-on-year and by 16% since the previous quarter
JSPR's equity has dropped by 63% year-on-year and by 32% since the previous quarter
Key stats
What are the main financial stats of JSPR
Market
Valuations
Earnings
Shares outstanding
15.02M
Market cap
$102.45M
Enterprise value
$55.82M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.43
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$82.97M
Net income
-$78.78M
EBIT
-$78.78M
EBITDA
-$76.85M
Free cash flow
-$70.21M
Per share
Balance sheet
Liquidity
EPS
-$5.26
EPS diluted
-$5.26
Free cash flow per share
-$4.67
Book value per share
$2.81
Revenue per share
$0
TBVPS
$3.83
Total assets
$57.6M
Total liabilities
$15.35M
Debt
$2.59M
Equity
$42.24M
Working capital
$40.84M
Debt to equity
0.06
Current ratio
4.31
Quick ratio
3.99
Net debt/EBITDA
0.61
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-89.8%
Return on equity
-109.5%
Return on invested capital
N/A
Return on capital employed
-174.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
JSPR stock price
How has the Jasper Therapeutics stock price performed over time
Intraday
18.82%
1 week
22.55%
1 month
25.14%
1 year
-70.06%
YTD
-68.1%
QTD
22.88%
Financial performance
How have Jasper Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$82.97M
Net income
-$78.78M
Gross margin
N/A
Net margin
N/A
Jasper Therapeutics's net income has decreased by 23% YoY and by 11% QoQ
The operating income has declined by 19% year-on-year and by 9% since the previous quarter
Price vs fundamentals
How does JSPR's price correlate with its fundamentals
Growth
What is Jasper Therapeutics's growth rate over time
Valuation
What is Jasper Therapeutics stock price valuation
P/E
N/A
P/B
2.43
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 8% since the previous quarter but it is up by 6% year-on-year
JSPR's equity has dropped by 63% year-on-year and by 32% since the previous quarter
The price to book (P/B) is 36% lower than the 5-year quarterly average of 3.8 and 29% lower than the last 4 quarters average of 3.4
Efficiency
How efficient is Jasper Therapeutics business performance
The company's return on equity has shrunk by 70% YoY and by 38% QoQ
The company's return on assets has shrunk by 60% YoY and by 32% QoQ
Dividends
What is JSPR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for JSPR.
Financial health
How did Jasper Therapeutics financials performed over time
JSPR's quick ratio has dropped by 70% year-on-year and by 16% since the previous quarter
The current ratio has plunged by 68% YoY and by 13% from the previous quarter
JSPR's debt is 94% lower than its equity
The debt to equity has surged by 200% year-on-year and by 100% since the previous quarter
JSPR's equity has dropped by 63% year-on-year and by 32% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.